Functional Effects of Glycosylation at Asn-579 of the Epidermal Growth Factor Receptor
Authors:
- Stefanie R. WhitsonSWStefanie R. Whitson
- Monica L. Red-BrewerMRMonica L. Red-Brewer
- Austin J. McCoyAMAustin J. McCoy
- Angela A. VitaliAVAngela A. Vitali
- Francesca WalkerFWFrancesca Walker
- Terrance G. JohnsTJTerrance G. Johns
- Albert H. BethABAlbert H. Beth
- James V. StarosJSJames V. Staros
- 19 October 2005
- journal article
- research article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 44 (45) , 14920-14931
Abstract
We have investigated functional effects of glycosylation at N579 of the epidermal growth factor receptor (EGFR). Our previous study showed that the population of cell-surface expressed EGFRs in A431 cells, a human epidermoid carcinoma cell line, is composed of two subpopulations that differ by glycosylation at N579 [Zhen et al. (2003) Biochemistry 42, 5478−5492]. To characterize the subpopulation of receptors not glycosylated at N579, we established a 32D cell line expressing a point mutant of the EGFR (N579Q), which cannot be glycosylated at this position. Analysis of epitope accessibility suggests that the lack of glycosylation at N579 weakens auto-inhibitory tether interactions, and cross-linking experiments suggest a somewhat elevated level of preformed N579Q-EGFR dimers in the absence of ligand relative to wild-type EGFR (WT-EGFR). However, ligand drives the majority of N579Q-EGFR dimerization, suggesting that untethering, while necessary, is not sufficient to drive dimerization. Ligand-binding experiments reveal a much greater fraction of N579Q-EGFRs in a high-affinity state compared to the fraction of WT-EGFRs in a high-affinity state. However, differences in the kinetic association and dissociation rates indicate that the high-affinity states of the WT and the N579Q receptors are distinct. EGF-stimulated phosphorylation in cells expressing N579Q-EGFRs results in notable differences in the pattern of tyrosine phosphorylated proteins compared with that obtained in cells expressing WT-EGFRs. Moreover, although WT-EGFRs confer cell survival in 32D cells in the absence of interleukin-3 and EGF, we found that receptors lacking glycosylation at N579 do not. This is the first study of which we are aware to show that selective glycosylation of a specific N-glycosylation site can produce two functionally distinct receptors.Keywords
This publication has 21 references indexed in Scilit:
- Fine Epitope Mapping of anti-Epidermal Growth Factor Receptor Antibodies Through Random Mutagenesis and Yeast Surface DisplayJournal of Molecular Biology, 2004
- Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the ReceptorJournal of Biological Chemistry, 2004
- Roles of N-Linked Glycans in the Endoplasmic ReticulumAnnual Review of Biochemistry, 2004
- The erbB Family: Targets for Therapeutic Development Against Cancer and Therapeutic Strategies Using Monoclonal Antibodies and Tyrosine Kinase InhibitorsAnnual Review of Medicine, 2004
- Epidermal growth factor receptor: mechanisms of activation and signallingExperimental Cell Research, 2003
- Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasiaSeminars in Oncology, 2002
- Disabling Receptor Ensembles with Rationally Designed Interface PeptidomimeticsJournal of Biological Chemistry, 2002
- The Asn-420-linked Sugar Chain in Human Epidermal Growth Factor Receptor Suppresses Ligand-independent Spontaneous OligomerizationJournal of Biological Chemistry, 2000
- The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactionsFEBS Letters, 1997
- Glycosylation of the Epidermal Growth Factor Receptor and Its Relationship to Membrane Transport and Ligand Binding1The Journal of Biochemistry, 1988